MY109958A - 5-aryl pyrimidine processes for its production and use as treatment for cns disorders - Google Patents

5-aryl pyrimidine processes for its production and use as treatment for cns disorders

Info

Publication number
MY109958A
MY109958A MYPI91000962A MYPI19910962A MY109958A MY 109958 A MY109958 A MY 109958A MY PI91000962 A MYPI91000962 A MY PI91000962A MY PI19910962 A MYPI19910962 A MY PI19910962A MY 109958 A MY109958 A MY 109958A
Authority
MY
Malaysia
Prior art keywords
processes
treatment
production
cns disorders
pyrimidine
Prior art date
Application number
MYPI91000962A
Other languages
English (en)
Inventor
Alan Skone Philip
Stuart Nobbs Malcolm
John Leach Michael
Iyer Ramachandran
Leonard Yeates Clive
Original Assignee
The Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Ltd filed Critical The Wellcome Foundation Ltd
Publication of MY109958A publication Critical patent/MY109958A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Paper (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MYPI91000962A 1990-06-01 1991-05-31 5-aryl pyrimidine processes for its production and use as treatment for cns disorders MY109958A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
MY109958A true MY109958A (en) 1997-10-31

Family

ID=10676964

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI91000962A MY109958A (en) 1990-06-01 1991-05-31 5-aryl pyrimidine processes for its production and use as treatment for cns disorders
MYPI95001459A MY136248A (en) 1990-06-01 1991-05-31 Pharmacologically active cns compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI95001459A MY136248A (en) 1990-06-01 1991-05-31 Pharmacologically active cns compounds

Country Status (25)

Country Link
EP (2) EP0459819B1 (index.php)
JP (1) JPH06340634A (index.php)
KR (1) KR920000733A (index.php)
AT (1) ATE141263T1 (index.php)
AU (2) AU652753B2 (index.php)
CA (1) CA2043640A1 (index.php)
CZ (1) CZ281070B6 (index.php)
DE (1) DE69121317T2 (index.php)
DK (1) DK0459819T3 (index.php)
ES (1) ES2093078T3 (index.php)
FI (1) FI912623A7 (index.php)
GB (1) GB9012316D0 (index.php)
GR (1) GR3021237T3 (index.php)
HU (2) HUT58707A (index.php)
IE (1) IE911861A1 (index.php)
IL (2) IL113599A (index.php)
MY (2) MY109958A (index.php)
NO (1) NO180375C (index.php)
NZ (3) NZ272001A (index.php)
PL (2) PL170373B1 (index.php)
PT (1) PT97827B (index.php)
RU (1) RU2091374C1 (index.php)
SK (1) SK278444B6 (index.php)
TW (1) TW224460B (index.php)
ZA (1) ZA914165B (index.php)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
FI20021701A7 (fi) * 1991-01-30 2002-09-24 The Wellcome Foundation Ltd Veteen dispergoituvia tabletteja
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
EP0674627A1 (en) * 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
KR100532546B1 (ko) 1999-09-16 2005-12-01 다나베 세이야꾸 가부시키가이샤 방향족 질소 함유 6-원 고리 화합물
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
US7220736B2 (en) 2000-04-28 2007-05-22 Tanabe Seiyaku Co., Ltd. Pyrimidine compounds
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
CA2438294C (en) 2001-02-26 2008-10-21 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
MXPA04007612A (es) * 2002-02-05 2004-11-10 Novo Nordisk As Aril- y heteroarilpiperazinas novedosas.
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
ATE536344T1 (de) 2005-07-04 2011-12-15 High Point Pharmaceuticals Llc Histamine h3 receptor antagonisten
CA2653062A1 (en) 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
MX2008014766A (es) 2006-05-29 2009-03-06 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)-piperazi na, sus sales y solvatos y su uso como antagonista del receptor de h3 histamina.
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
CN106831732B (zh) * 2011-06-10 2019-12-24 默克专利有限公司 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
CA3023216A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US20190343836A1 (en) 2017-01-10 2019-11-14 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (index.php) *
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
NO180375B (no) 1996-12-30
DE69121317T2 (de) 1997-01-02
AU6745594A (en) 1994-09-15
AU680252B2 (en) 1997-07-24
FI912623A0 (fi) 1991-05-31
IL113599A (en) 1997-09-30
AU7809791A (en) 1991-12-05
KR920000733A (ko) 1992-01-29
PL170373B1 (pl) 1996-12-31
FI912623A7 (fi) 1991-12-02
NO912100L (no) 1991-12-02
IE911861A1 (en) 1991-12-04
GB9012316D0 (en) 1990-07-18
AU652753B2 (en) 1994-09-08
CZ281070B6 (cs) 1996-06-12
IL113599A0 (en) 1995-08-31
DE69121317D1 (de) 1996-09-19
TW224460B (index.php) 1994-06-01
ZA914165B (en) 1993-03-01
PL166656B1 (pl) 1995-06-30
CS164391A3 (en) 1992-02-19
ATE141263T1 (de) 1996-08-15
ES2093078T3 (es) 1996-12-16
EP0459819A2 (en) 1991-12-04
RU2091374C1 (ru) 1997-09-27
EP0459819A3 (en) 1992-03-11
CA2043640A1 (en) 1991-12-02
DK0459819T3 (da) 1996-09-02
PT97827A (pt) 1992-03-31
SK278444B6 (en) 1997-05-07
HU911826D0 (en) 1991-12-30
EP0459819B1 (en) 1996-08-14
NZ272001A (en) 1997-03-24
NZ248501A (en) 1997-03-24
GR3021237T3 (en) 1997-01-31
HU211649A9 (en) 1995-12-28
NO912100D0 (no) 1991-05-31
IL98330A0 (en) 1992-06-21
EP0679645A1 (en) 1995-11-02
JPH06340634A (ja) 1994-12-13
NO180375C (no) 1997-04-09
NZ238360A (en) 1997-03-24
MY136248A (en) 2008-08-29
HUT58707A (en) 1992-03-30
IL98330A (en) 1996-10-31
PT97827B (pt) 1998-10-30

Similar Documents

Publication Publication Date Title
MY109958A (en) 5-aryl pyrimidine processes for its production and use as treatment for cns disorders
MY115951A (en) Pharmacologically active cns compounds
PH30118A (en) Phenylsulfonylamide pyrimidine
NZ516562A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
NZ290389A (en) Substituted pyrimidines typically substituted by -piperazin-1-yl
NZ326754A (en) The use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene or salts thereof for the prophylaxis and treatment of sequelae of chronic reduced circulation in the brain in particular strokes and for neurodegenerative disorders
PT871448E (pt) Compostos de aril e heteroaril-quinazolina que inibem a tirosina-cinase do receptor csf-1r
MY110871A (en) Novel sulfonylamino pyrimidines
NZ517616A (en) Use of retigabin for treating neuropathic pain
HU9601790D0 (en) Diazabicyclic neurokinin antagonists
ATE251613T1 (de) Pyrimidinonderivate zur behandlung von atheroscleros
GB0005345D0 (en) Methods of treating sepsis septic shock and inflammation
SI1173439T1 (en) Haloalkoxy imidazonaphthyridines
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
MY127686A (en) Monofluoroalkyl derivatives
MY121864A (en) Condensed thienopyrimidines with phosphodiesterase-v inhibiting action.
NO951261D0 (no) Opplagring for en del av et banelegeme
IL89278A0 (en) Tetrazole excitatory amino acid receptor antagonists
IL106492A0 (en) Water-dispersible tables
MXPA04005129A (es) Uso de diamina de acido piridin-2,4-dicarboxilico y de diaminas de acido pirimidin-4,6-dicarboxilico para la inhibicion selectiva de la colagenasa.
MXPA02007403A (es) Derivados de pirrol, sustituidos con 4-piridilo y 2,4-pirimidinilo, y su uso en farmacia.
SG44827A1 (en) Compounds useful as antiproliferative agents and garft inhibitors
DK0691846T3 (da) Imidazoquinoxalinoner til behandling af sygdomme i centralnervesystemet
MX9705390A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis de desordenes degenerativos cerebrales.